2025

Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry’s Largest NGS-Based Proteomics Panel

FOSTER CITY, Calif.–(BUSINESS WIRE)–Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, announced today an Illumina-sponsored grant for Early Access to Illumina Protein Prep 9.5K™. Powered by SOMAmer® technology, this next-generation sequencing (NGS)-based platform enables comprehensive proteomic profiling of plasma and serum. Illumina Protein Prep 9.5K™ utilizes slow off-rate […]

Signios Bio Launches with AI-Driven Bioinformatics and Advanced Multiomics Platform to Power the Future of Precision Medicine and Drug Discovery

FOSTER CITY, California, APRIL 10, 2025 — Signios Biosciences (“Signios Bio”), a science-first biotechnology company at the forefront of multiomics and AI-powered bioinformatics, today announced its rebranding from its previous identity as the US based research division of MedGenome Inc. This milestone marks a new era, better positioning the brand in the US on its